Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519531 · ClinicalTrials.gov registry record · Phase 1
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects
A Phase 1 study of Drug Safety, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01519531 is a Phase 1 study of Drug Safety that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 48 participants, below the 92-participant average among 4 other Drug Safety trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01519531, a Phase 1 study of Drug Safety, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, randomized, double-blind, placebo-controlled, ascending multiple-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matching placebo. Subjects will be dosed daily for 14 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VIA-3196
Study Locations (1)
North Dakota
- PRACS Institute (formerly Cetero Research) - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01519531
The ClinicalTrials.gov registry entry for NCT01519531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 4 other Drug Safety trials with a reported enrollment target (48% lower). The listed sponsor is Madrigal Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Safety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01519531 reports 1 study location spanning 1 distinct geographic area - top geographies include North Dakota.
Frequently Asked Questions
What is clinical trial NCT01519531 about?
NCT01519531 is a clinical study titled "Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects". This is a single-center, randomized, double-blind, placebo-controlled, ascending multiple-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matc...
What is the current status of trial NCT01519531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-01. Estimated completion is 2012-11.
What conditions does trial NCT01519531 study?
This clinical trial studies the following conditions: Drug Safety.
What interventions are being tested in trial NCT01519531?
The interventions under investigation include: Placebo (DRUG), VIA-3196 (DRUG).
Who is sponsoring clinical trial NCT01519531?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01519531 being conducted?
This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Safety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects
COMPLETED · Phase 1
-
Clinical Safety of a Novel Milk Protein Peptide
COMPLETED · Phase 1
-
Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase
ACTIVE NOT RECRUITING · Early Phase 1
-
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.